These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7755488)

  • 1. Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats.
    Adachi J; Gomez M; Smith CC; Sternberg EM
    Arch Toxicol; 1995; 69(4):266-70. PubMed ID: 7755488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of four metabolites of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in rats.
    Adachi J; Mio T; Ueno Y; Naito T; Nishimura A; Fujiwara S; Sumino K; Tatsuno Y
    Arch Toxicol; 1994; 68(8):500-5. PubMed ID: 7802590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.
    Sato F; Hagiwara Y; Kawase Y
    Arch Toxicol; 1995; 69(7):444-9. PubMed ID: 8526739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
    Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
    Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome.
    Mayeno AN; Benson LM; Naylor S; Colberg-Beers M; Puchalski JT; Gleich GJ
    Chem Res Toxicol; 1995; 8(7):911-6. PubMed ID: 8555405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome.
    Martínez-Cabot A; Messeguer A
    Chem Res Toxicol; 2007 Oct; 20(10):1556-62. PubMed ID: 17892268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of 1-methyl-tetrahydro-beta-carboline-3-carboxylic acid in blood and organs of rat. A possible causative substance of eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan.
    Ogawa Y; Adachi J; Tatsuno Y
    Arch Toxicol; 1993; 67(4):290-3. PubMed ID: 8517786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and distribution in the rat of peak E substance, a constituent in L-tryptophan product implicated in eosinophilia-myalgia syndrome.
    Adachi J; Naito T; Ueno Y; Ogawa Y; Ninomiya I; Tatsuno Y
    Arch Toxicol; 1993; 67(4):284-9. PubMed ID: 8517785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 3-phenylamino-L-alanine on tryptophan binding to rat hepatic nuclear envelopes.
    Sidransky H; Verney E; Cosgrove JW; Latham PS
    Toxicology; 1994 Jan; 86(1-2):135-45. PubMed ID: 8134920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of tissue distribution and excretion among three substances implicated in eosinophilia-myalgia syndrome.
    Adachi J; Ueno Y; Tatsuno Y; Gomez M; Smith CC; Sternberg EM
    Adv Exp Med Biol; 1996; 398():365-70. PubMed ID: 8906290
    [No Abstract]   [Full Text] [Related]  

  • 11. On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome.
    Williamson BL; Benson LM; Tomlinson AJ; Mayeno AN; Gleich GJ; Naylor S
    Toxicol Lett; 1997 Jul; 92(2):139-48. PubMed ID: 9295237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and analysis of contaminants in ems-related tryptophan.
    Steinhart H; van Wickern B; Meyer K; Simat T
    Adv Exp Med Biol; 1996; 398():667-75. PubMed ID: 8906342
    [No Abstract]   [Full Text] [Related]  

  • 13. L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat.
    Crofford LJ; Rader JI; Dalakas MC; Hill RH; Page SW; Needham LL; Brady LS; Heyes MP; Wilder RL; Gold PW
    J Clin Invest; 1990 Nov; 86(5):1757-63. PubMed ID: 2243145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrahydro-beta-carboline-3-carboxylic acids and contaminants of L-tryptophan.
    Adachi J; Asano M; Ueno Y
    J Chromatogr A; 2000 Jun; 881(1-2):501-15. PubMed ID: 10905731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome.
    Naylor S; Williamson BL; Johnson KL; Gleich GJ
    Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,1'-Ethylidenebis[tryptophan] induces pathologic alterations in muscle similar to those observed in the eosinophilia-myalgia syndrome.
    Emslie-Smith AM; Mayeno AN; Nakano S; Gleich GJ; Engel AG
    Neurology; 1994 Dec; 44(12):2390-2. PubMed ID: 7991132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,1'-Ethylidenebis[L-tryptophan], a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome, suppresses mRNA expression of hypothalamic corticotropin-releasing hormone in Lewis (LEW/N) rat brain.
    Brady LS; Page SW; Thomas FS; Rader JL; Lynn AB; Misiewicz-Poltorak B; Zelazowski E; Crofford LJ; Zelazowski P; Smith C
    Neuroimmunomodulation; 1994 Jan; 1(1):59-65. PubMed ID: 8528886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.
    Takagi H; Ochoa MS; Zhou L; Helfman T; Murata H; Falanga V
    J Clin Invest; 1995 Nov; 96(5):2120-5. PubMed ID: 7593596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated L-tryptophan samples.
    Goda Y; Suzuki J; Maitani T; Yoshihira K; Takeda M; Uchiyama M
    Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2236-8. PubMed ID: 1423790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.